Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
HOME > LATEST
LATEST
-
REGULATORY Industry Explains Scheme to Deal with New Self-Inspection Asked for All Generic Makers
March 19, 2024
-
REGULATORY Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
March 19, 2024
-
BUSINESS Shonan iPark Launches Local Post in South Korea
March 19, 2024
-
ORGANIZATION Biosafety Rules Tied to Gene Therapy Put Heavy Financial Burden on Hospitals: Expert
March 19, 2024
-
REGULATORY Japan to Work towards Ensuring Consistency in Different Clinical Trial Laws
March 19, 2024
-
REGULATORY Japan Panel to Discuss Fate of SanBio’s Sakigake Cell Therapy amid Stalled Review
March 19, 2024
-
BUSINESS ASKA Ties Up with Red Arrow on Novel Preeclampsia Treatment
March 19, 2024
-
BUSINESS Canaglu OD Tablet Version Approved in Japan
March 19, 2024
-
BUSINESS FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
-
BUSINESS Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
-
ORGANIZATION Doctors’ Groups Call for Cross-Ministerial Efforts to Spur Genomic Medicine
March 18, 2024
-
ACADEMIA Lecanemab Combo Trial Launched in Japan for Familial Alzheimer’s
March 18, 2024
-
REGULATORY Japan to Cap COVID Vaccine Copay at 7,000 Yen under NIP
March 18, 2024
-
BUSINESS BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
-
BUSINESS Daiichi Sankyo Offers Hefty 7%-Plus Pay Hike in 2024
March 18, 2024
-
BUSINESS Bimzelx’s 320 mg Auto-Injector Version Filed in Japan: UCB
March 18, 2024
-
REGULATORY Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
March 18, 2024
-
REGULATORY Another Daiichi Sankyo Veteran to Take Over as Provost of SCARDA
March 15, 2024
-
REGULATORY Japan Begins Discussions on RSV Vaccines for National Immunization Program
March 15, 2024
-
REGULATORY Japan to Set Value-Based Share of 65% as Secondary Target for Generic Use
March 15, 2024
ページ
Your reputation as an employer matters.A survey completed by Indeed found that 95% of job seekers found a company’s reputation was an important consideration.When top talent is a scarce commodity, companies need to do more than just make an offer.…
A health ministry panel on pharmaceutical regulations on December 13 discussed the need for confirmatory trial data in Japanese subjects for drugs to treat ultra-rare diseases. The industry proposed waving the implementation of Japanese studies when deemed appropriate in a…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…